Neovascular age-related macular degeneration and the risk of stroke: A 5-year population-based follow-up study

Stroke

Volumn 41, Issue 4, 2010, Pages 613-617

  Hu, Chao Chien ^a,b,c,d   Ho, Jau Der ^a,b   Lin, Herng Ching ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^d FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

AMD; Neovascular age related macular degeneration; Stroke

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMMUNITY; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; EVENT FREE SURVIVAL; FEMALE; GENDER; GROUPS BY AGE; HAZARD RATIO; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INCOME; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RISK FACTOR; STROKE; URBANIZATION;

AGED; COHORT STUDIES; FOLLOW-UP STUDIES; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; RISK FACTORS; STROKE; TAIWAN;

EID: 77950243399     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.571000     Document Type: Article

References (28)

1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291:1900-1901.
2. Congdon N, O'Colmain B, Klaver CC, Klein R, Munoz B, Friedman DS, Kempen J, Taylor HR, Mitchell P. Causes and prevalence of visual impairment among adults in the united states. Arch Ophthalmol. 2004; 122:477-485.
3. Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122: 564-572.
4. Hsu WM, Cheng CY, Liu JH, Tsai SY, Chou P. Prevalence and causes of visual impairment in an elderly Chinese population in Taiwan: the Shihpai Eye Study. Ophthalmology. 2004;111:62-69.
5. Klein R, Klein BE, Lee KE, Cruickshanks KJ, Gangnon RE. Changes in visual acuity in a population over a 15-year period: the Beaver Dam Eye Study. Am J Ophthalmol. 2006;142:539-549.
6. Buch H, Nielsen NV, Vinding T, Jensen GB, Prause JU, la Cour M. 14-year incidence, progression, and visual morbidity of age-related macu-lopathy: the Copenhagen City Eye Study. Ophthalmology. 2005;112: 787-798.
7. Attebo K, Mitchell P, Smith W. Visual acuity and the causes of visual loss in Australia. The Blue Mountains Eye Study. Ophthalmology. 1996;103: 357-364.
8. Klein R, Klein BE, Marino EK, Kuller LH, Furberg C, Burke GL, Hubbard LD. Early age-related maculopathy in the Cardiovascular Health Study. Ophthalmology. 2003;110:25-33.
9. Wong TY, Klein R, Sun C, Mitchell P, Couper DJ, Lai H, Hubbard LD, Sharrett AR. Age-related macular degeneration and risk for stroke. Ann Intern Med. 2006;145:98-106.
10. Sun C, Klein R, Wong TY. Age-related macular degeneration and risk of coronary heart disease and stroke: the Cardiovascular Health Study. Ophthalmology. 2009;116:1913-1919.
11. Alexander SL, Linde-Zwirble WT, Werther W, Depperschmidt EE, Wilson LJ, Palanki R, Saroj N, Butterworth SL, Ianchulev T. Annual rates of arterial thromboembolic events in Medicare neovascular age-related macular degeneration patients. Ophthalmology. 2007;114:2174-2178.
12. Tan JS, Wang JJ, Liew G, Rochtchina E, Mitchell P. Age-related macular degeneration and mortality from cardiovascular disease or stroke. Br J Ophthalmol. 2008;92:509-512.
13. Liao D, Mo J, Duan Y, Klein R, Scott IU, Huang KA, Zhou H. Is age-related macular degeneration associated with stroke among elderly Americans? Open Ophthalmol J. 2008;2:37-42.
14. Pauleikhoff D, Chen JC, Chisholm IH, Bird AC. Choroidal perfusion abnormality with age-related Bruch's membrane change. Am J Oph-thalmol. 1990;109:211-217.
15. Friedman E. The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. Am J Ophthalmol. 2000;130:658-663.
16. Curcio CA, Millican CL, Bailey T, Kruth HS. Accumulation of cholesterol with age in human Bruch's membrane. Invest Ophthalmol Vis Sci. 2001;42:265-274.
17. Gentile R. More research is needed to support the association of AMD and stroke age-related macular degeneration and risk for stroke, by TY Wong, R Klein, C Sun, P Mitchell, D Couper, H Lai, LD Hubbard, and AR Sharrett, atherosclerosis risk in communities study. Ann Intern Med 145:98-107, 2006. Surv Ophthalmol. 2007;52:551-553.
18. Kuehn BM. Gene discovery provides clues to cause of age-related macular degeneration. JAMA. 2005;293:1841-1845.
19. Di Napoli M. Systemic complement activation in ischemic stroke. Stroke. 2001;32:1443-1448.
20. Edwards AO, Ritter R III, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308:421-424.
21. Wen F, Chen C, Wu D, Li H. Polypoidal choroidal vasculopathy in elderly Chinese patients. Graefes Arch Clin Exp Ophthalmol. 2004;242: 625-629.
22. Yannuzzi LA, Wong DW, Sforzolini BS, Goldbaum M, Tang KC, Spaide RF, Freund KB, Slakter JS, Guyer DR, Sorenson JA, Fisher Y, Maberley D, Orlock DA. Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. Arch Ophthalmol. 1999;117: 1503-1510.
23. Nakashizuka H, Mitsumata M, Okisaka S, Shimada H, Kawamura A, Mori R, Yuzawa M. Clinicopathologic findings in polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci. 2008;49:4729-4737.
24. Fung AE, Rosenfeld PJ, Reichel E. The international intravitreal bev-acizumab safety survey: using the Internet to assess drug safety worldwide. Br J Ophthalmol. 2006;90:1344-1349.
25. Dafer RM, Schneck M, Friberg TR, Jay WM. Intravitreal ranibizumab and bevacizumab: a review of risk. Semin Ophthalmol. 2007;22:201-204.
26. Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT, Emerson GG, Schlesinger TK, Nolte SK, Klein ML. Intravitreal bev-acizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina. 2007;27:439-444.
27. Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG. A phase IIIB study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology. 2009; 116:1731-1739.
28. Wong TY. Age-related macular degeneration and cardiovascular disease in the era of anti-vascular endothelial growth factor therapies. Am J Ophthalmol. 2009;148:327-329.